BNCT for recurrent head and neck cancer
Part of Cancer clinical trials.
This trial tests a special type of radiation therapy called BNCT (boron neutron capture therapy) for head and neck cancers that have come back and cannot be removed by surgery. It may be an option for patients who have already had radiation and cannot receive standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have head and neck cancer that has come back and cannot be surgically removed, and has not spread to other parts of the body.
- You have already received some type of radiation therapy to the head and neck area, and it has been at least 3 months since that treatment.
- Your main tumor can be seen on an MRI or CT scan and is smaller than about 7 centimeters (2.8 inches).
- You are generally healthy enough to undergo treatment, with good blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This trial tests a new way of giving radiation therapy, called adaptive radiation boost, for people with head and neck cancer. The goal is to see if this approach can better target the cancer and possibly improve outcomes.
This trial tests a special type of radiation therapy called boron neutron capture therapy (BNCT) for people with high-grade malignant brain tumors. It aims to see if BNCT is safe and effective for tumors that have not been treated or have come back after standard treatments.
This trial tests a type of radiation therapy called BNCT (boron neutron capture therapy) for people with head and neck cancer that cannot be surgically removed. It may be an option if you have already had radiation or chemo and have no distant spread of cancer.
This trial tests whether adding BMX-001 (a drug that may protect healthy tissues) to standard chemoradiation can reduce side effects and improve outcomes for people with head and neck cancer. It's a randomized study, so you would have a 50/50 chance of getting BMX-001 or a placebo.
This early-phase trial tests a new combination of drugs (CICS-1 and SPM-011) along with a special imaging scan to see if they can help people with hard-to-treat cancers that have come back. It may be an option if standard treatments are no longer working.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.